Clinical Research Center for Organ Transplantation in Hunan Province, Changsha, China.
Department of Organ Procurement Organization, The Second Xiangya Hospital of Central South University, Changsha, China.
BMC Nephrol. 2023 Jun 8;24(1):163. doi: 10.1186/s12882-023-03226-x.
Changes of serum galectin-3 (Gal-3) is associated with the pathogenesis of diabetic nephropathy (DN). However, current literature indicates that the given results remain debatable and inconsistent. Hence, the aim of this present meta-analysis was to focus on the predictive role of serum Gal-3 in patients with DN.
The PubMed, Embase, Cochrane Library and Web of Science databases were systematically searched for studies that reported the relationship between Gal-3 levels and DN risk, from the inception of each database to March, 2023. The literature we selected for inclusion based on inclusion and exclusion criteria. The standard mean difference (SMD) with corresponding 95% confidence intervals (95% CI) were used to investigate the association. When I value exceeding 50%, we will consider it has the presence of a higher level of heterogeneity. A sensitivity analysis and subgroup analysis were performed to seek the potential sources of heterogeneity. The quality assessment was performed using according to the Newcastle-Ottawa Quality Assessment Scale (NOS). The data analysis was conducted using STATA version 13.0 software.
We ultimately enrolled 9 studies enrolling a total of 3137 patients in the final analysis. The SMD of serum Gal-3 was higher in patients with DN group (SMD 1.10 ng/mL [0.63, 1.57]; I: 96.1%). Upon removal of a study in sensitivity analysis, patients with DN had higher serum Gal-3 levels compared to control patients (SMD 1.03 ng/mL [0.52, 1.54], I: 94.4%). Further subgroup analysis was performed based on the region. No matter in Asia, Europe or Africa, the serum Gal-3 level of DN patients is significantly higher than that of the control population (SMD: 0.73; 95% CI: 0.58 to 0.87 for Asian; SMD: 0.79; 95% CI: 0.48 to 1.10 for Europe; SMD: 3.15; 95% CI: 2.73 to 3.56 for Africa).
In conclusion, these results suggested that higher serum Gal-3 may increase the risk of DN. More fundamental studies are necessary to clarify the exact physiopathological basis mechanisms of Gal-3 effects. In addition, further research, especially emphasis on the cut-off value should be given, and is best to predict their actual importance as well as the diagnostic accuracy.
血清半乳糖凝集素-3(Gal-3)的变化与糖尿病肾病(DN)的发病机制有关。然而,目前的文献表明,给出的结果仍然存在争议和不一致。因此,本荟萃分析的目的是关注血清 Gal-3 在 DN 患者中的预测作用。
系统检索了 PubMed、Embase、Cochrane 图书馆和 Web of Science 数据库,以检索截至 2023 年 3 月报告 Gal-3 水平与 DN 风险之间关系的研究。我们根据纳入和排除标准选择纳入的文献。使用标准均数差(SMD)及其相应的 95%置信区间(95%CI)来研究相关性。当 I 值超过 50%时,我们将认为存在更高水平的异质性。进行敏感性分析和亚组分析以寻找潜在的异质性来源。使用纽卡斯尔-渥太华质量评估量表(NOS)进行质量评估。使用 STATA 版本 13.0 软件进行数据分析。
我们最终纳入了 9 项研究,共纳入 3137 名患者进行最终分析。DN 组患者的血清 Gal-3 SMD 较高(SMD 1.10ng/mL [0.63,1.57];I:96.1%)。在敏感性分析中删除一项研究后,DN 患者的血清 Gal-3 水平高于对照组患者(SMD 1.03ng/mL [0.52,1.54],I:94.4%)。进一步根据地区进行亚组分析。无论在亚洲、欧洲还是非洲,DN 患者的血清 Gal-3 水平均明显高于对照组人群(SMD:0.73;95%CI:0.58 至 0.87 为亚洲;SMD:0.79;95%CI:0.48 至 1.10 为欧洲;SMD:3.15;95%CI:2.73 至 3.56 为非洲)。
总之,这些结果表明,较高的血清 Gal-3 可能会增加 DN 的风险。需要进一步的基础研究来阐明 Gal-3 作用的确切病理生理基础机制。此外,应进一步研究,特别是强调截断值,并最好预测其实际重要性及其诊断准确性。